C
Claus Garbe
Researcher at University of Tübingen
Publications - 835
Citations - 59830
Claus Garbe is an academic researcher from University of Tübingen. The author has contributed to research in topics: Melanoma & Vemurafenib. The author has an hindex of 101, co-authored 801 publications receiving 52175 citations. Previous affiliations of Claus Garbe include James Cook University.
Papers
More filters
Journal ArticleDOI
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Paul B. Chapman,Axel Hauschild,Caroline Robert,John B. A. G. Haanen,Paolo A. Ascierto,James Larkin,Reinhard Dummer,Claus Garbe,Alessandro Testori,Michele Maio,David W. Hogg,Paul Lorigan,Céleste Lebbé,Thomas Jouary,Dirk Schadendorf,Antoni Ribas,Jeffrey A. Sosman,John M. Kirkwood,Brigitte Dréno,K. B. Nolop,Jiang Li,B. Nelson,Jeannie Hou,Richard J. Lee,Keith T. Flaherty,Grant A. McArthur +25 more
TL;DR: Vemurafenib produced improved rates of overall and progression-free survival in patients with previously untreated melanoma with the BRAF V600E mutation in a phase 3 randomized clinical trial.
Journal ArticleDOI
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Caroline Robert,Luc Thomas,Igor Bondarenko,Steven J. O'Day,Jeffrey S. Weber,Claus Garbe,Céleste Lebbé,Jean Francois Baurain,Alessandro Testori,Jean-Jacques Grob,Neville Davidson,Jon M. Richards,Michele Maio,Axel Hauschild,Wilson H. Miller,Pere Gascón,Michal Lotem,Kaan Harmankaya,Ramy Ibrahim,Stephen Francis,Tai-Tsang Chen,R. Humphrey,Axel Hoos,Jedd D. Wolchok +23 more
TL;DR: Ipilimumab (at a dose of 10 mg per kilogram) in combination with dacarbazine, as compared with dACarbazine plus placebo, improved overall survival in patients with previously untreated metastatic melanoma.
Journal ArticleDOI
Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
Keith T. Flaherty,Caroline Robert,Peter Hersey,Paul C. Nathan,Claus Garbe,Mohammed M. Milhem,Lev V. Demidov,Jessica C. Hassel,Piotr Rutkowski,Peter Mohr,Reinhard Dummer,Uwe Trefzer,James Larkin,Jochen Utikal,Brigitte Dréno,Marta Nyakas,Mark R. Middleton,Juergen C. Becker,Michelle Casey,Laurie Sherman,Frank S. Wu,Daniele Ouellet,Anne-Marie Martin,Kiran Patel,Dirk Schadendorf +24 more
TL;DR: Tametinib, as compared with chemotherapy, improved rates of progression-free and overall survival among patients who had metastatic melanoma with a BRAF V600E or V600K mutation.
Journal ArticleDOI
Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma
James Larkin,Paolo A. Ascierto,Brigitte Dréno,Victoria Atkinson,Gabriella Liszkay,Michele Maio,Mario Mandalà,Lev V. Demidov,Daniil Stroyakovskiy,Luc Thomas,Luis de la Cruz-Merino,Caroline Dutriaux,Claus Garbe,Mika A. Sovak,Ilsung Chang,Nicholas Choong,Stephen P. Hack,Grant A. McArthur,Antoni Ribas +18 more
TL;DR: The addition of cobimetinib to vemurafenib was associated with a significant improvement in progression-free survival among patients with BRAF V600-mutated metastatic melanoma, at the cost of some increase in toxicity.
Journal ArticleDOI
Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma
Georgina V. Long,Daniil Stroyakovskiy,Helen Gogas,Evgeny Levchenko,F. de Braud,James Larkin,Claus Garbe,T. Jouary,Axel Hauschild,Jean-Jacques Grob,V. Chiarion Sileni,Céleste Lebbé,Mario Mandalà,Michael Millward,Ana Arance,Igor Bondarenko,John B. A. G. Haanen,Johan Hansson,Jochen Utikal,Virginia Ferraresi,Nadezhda Kovalenko,Peter Mohr,V. Probachai,Dirk Schadendorf,Paul Nathan,Caroline Robert,Antoni Ribas,Douglas J. DeMarini,Jhangir G. Irani,Michelle Casey,Daniele Ouellet,Anne-Marie Martin,Ngocdiep T. Le,Kiran Patel,Keith T. Flaherty +34 more
TL;DR: A combination of dabraenib and trametinib, as compared with dabrafenib alone, improved the rate of progression-free survival in previously untreated patients who had metastatic melanoma with BRAF V600E or V600K mutations.